2024 ISPE Biotechnology Conference

Overview

The 2024 ISPE Biotechnology Conference will bring together leading pharmaceutical and biopharmaceutical manufacturers, technology providers, academic scientists, and international regulators to network, share insights, and provide an outlook on the evolving landscape and future of the development and manufacturing of biotechnology products.

This conference will focus on unique challenges associated with innovative pharmaceutical products applied and transferred to the (new) biosimilar, bio better, and follow-up biotechnology products, like cell and gene therapy, Advanced Therapeutic Medicinal Products (ATMPs), and mRNA-based product development and new applications. In addition, the conference will feature presentations with a focus on enablers for process development, speed-to-market, sustainability, product technology transfer, new concepts for control strategy, and manufacturing.

Throughout this event, we will discuss and consider key areas and advancements in biotechnology:

Robotic arm

Artificial Intelligence

AI can potentially streamline various operational processes via enhanced automation. Explore the impact of automation and augmentation on innovative processes like ATMPs and gene therapy, redefining how we work.

Technical Presentation

Data Science-Assisted Tech Transfer

There is more data to analyze than ever before. A top priority for companies includes finding ways to increase automation, data accessibility, and speed. Learn how to utilize data science in biopharmaceutical tech transfer and process characterization, and how to address challenges and regulatory expectations.

Case Studies

Sustainability

Delve into innovative strategies and technologies to increase sustainability and reduce the environmental impact of the biopharmaceutical industry.

Case Studies

Quality and Regulatory

Discover the added value of digitalized Quality Management in ensuring the effectiveness and compliance of quality systems, for reduced inspection risks, and support for a more reliable drug supply chain.

Case Studies

Novel Technology Innovations

Uncover technological advancements in pharmaceutical manufacturing, including the expedited production of innovative therapies and the integration of robotics and single-use systems to meet current regulatory demands.

Case Studies

Lifecycle Strategies

Dive into strategies for accelerating commercialization and time-to-market through the product life cycle. The conference will feature approaches aimed at reducing development cycles and enhancing the introduction of processes into facilities.

Case Studies

Facility Design

Explore the challenges, trends, and driving factors behind Biopharmaceutical Facility Design, such as facility planning considerations, economic viability, and regulatory requirements from a CCS and QRM perspective.

Case Studies

Expert Insights

Expert Insights: Hear from industry leaders and regulators who will share their perspectives on the future of pharmaceuticals.


Featured Speakers

Sharmista Chatterjee, PhD
Division Director
FDA, OPMA
Rene-Pascal Fischer
Scientist & Software Architect
Fraunhofer IESE
Robert S. Langer, PhD
Institute Professor
Massachusetts Institute of Technology
Piper Trelstad, PhD
Head of Chemistry, Manufacturing & Controls
Bill & Melinda Gates Medical Research Institute

Conference Topics

The 2024 Biotechnology Conference program committee is requesting proposals aligning with the following content areas:

Hear What Our Past Attendees Are Saying


Conference Highlights

Receive Notifications

Stay up-to-date on registration, education opportunities, speakers, hotel discounts, exhibitor information, and more by signing up to receive notifications for the 2024 ISPE Biotechnology Conference.

Name
Company Type
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

AnchorInternational Program Committee

Phillip R. Smith, PhD
Director, Process Technology
GlaxoSmithKline
Chair
Vivianne J. Arencibia
Vice President, Global Quality Systems and Compliance
Moderna
International Board Liaison/Foundation Board Liaison
Yolanda McLean
Senior Director, Quality Control
Alnylam Pharmaceuticals
Women in Pharma Liaison
Laura-Ann Shaa Ling Chin, BSc, MSc, PE
Director, Life Sciences
Barry-Wehmiller Design Group
Richard Denk
Senior Consultant Aseptic Processing & Containment
SKAN AG
David Doleski
Head of Global Quality Audit and External Engagement
Sanofi
Liz M. Dooley, MSc
Senior Director, Global Engineering & Technology
Johnson & Johnson
Jean-François Duliere
Regulatory Advisor
ISPE
Prudence Edwards
Operational Excellence Specialist
Thermo Fisher Scientific Brisbane, Australia
Ylva Ek
Founder
Robur Life Science Advisory AB
David Estapé, PhD
Technology Manager Biotechnology
CRB Group GmbH
Placeholder Person Graphic
Meli Gallup
Genentech Inc
Christoph Herwig, PhD
Senior Scientific Advisor
Körber Pharma Austria
Antonio R. Moreira, PhD
Vice Provost, Academic Affairs
University of Maryland
Thomas Zahel, PhD
Head of Innovation
Körber Pharma Austria GmbH
Placeholder Person Graphic
Nicholas Frechette
Senior Project Engineer
Barry-Wehmiller Design Group
Emerging Leader
Laura Kuger
PhD Candidate
Karlsruhe Institute of Technology (KIT)
Emerging Leader
Ryan Paul Mazur
Process Engineer II
Genesis AEC
Emerging Leader
Joseph Olewinski
Quality Engineer
Barry-Wehmiller Design Group
Emerging Leader
Hilal Yamaner
Process Engineer
VTU Engineering Schweiz AG
Emerging Leader

Conference Sponsors

Arcadis

Project Farma

Valgenesis